Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Teva Pharmaceutical Industries ADR (TEVA)

Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,597,198
  • Shares Outstanding, K 1,149,813
  • Annual Sales, $ 17,258 M
  • Annual Income, $ 1,411 M
  • EBIT $ 2,417 M
  • EBITDA $ 3,419 M
  • 60-Month Beta 0.72
  • Price/Sales 1.91
  • Price/Cash Flow 7.70
  • Price/Book 4.18

Options Overview Details

View History
  • Implied Volatility 48.15% (-2.47%)
  • Historical Volatility 35.74%
  • IV Percentile 74%
  • IV Rank 39.82%
  • IV High 80.64% on 09/09/25
  • IV Low 26.66% on 12/10/25
  • Expected Move (DTE 2) 0.62 (2.06%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 29,889
  • Volume Avg (30-Day) 14,398
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 428,223
  • Open Int (30-Day) 385,187
  • Expected Range 29.50 to 30.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.55
  • Number of Estimates 3
  • High Estimate $0.58
  • Low Estimate $0.52
  • Prior Year $0.49
  • Growth Rate Est. (year over year) +12.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.28 +6.49%
on 03/30/26
34.20 -11.93%
on 03/02/26
-3.74 (-11.05%)
since 02/27/26
3-Month
28.28 +6.49%
on 03/30/26
37.35 -19.35%
on 02/03/26
-1.77 (-5.55%)
since 12/26/25
52-Week
12.47 +141.64%
on 04/10/25
37.35 -19.35%
on 02/03/26
+15.04 (+99.73%)
since 03/28/25

Most Recent Stories

More News
Viatris Stock: Is VTRS Outperforming the Health Care Sector?

As Viatris has outperformed the broader health care sector over the past year, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 146.61 (+1.94%)
VTRS : 13.51 (+4.24%)
TEVA : 30.12 (+6.24%)
Google's New Frontier: How Alphabet Becomes the Next Healthcare Titan with AI

Alphabet Inc. (GOOGL) is strategically evolving from a digital search leader to a healthcare powerhouse, aiming to solve the "broken" pharmaceutical model. With traditional drug development costing $2.5...

GOOG : 286.86 (+5.02%)
GOOGL : 287.56 (+5.14%)
TEVA : 30.12 (+6.24%)
The Saturday Spread: Letting the Smart Money Act as an Early Warning Sign

Since the most sophisticated market participants have access to resources that regular folks lack, their posture can clue us into potential sentiment swings.

NEM : 108.25 (+4.97%)
RIVN : 15.05 (+3.86%)
TEVA : 30.12 (+6.24%)
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...

RPRX : 47.97 (+3.45%)
TEVA : 30.12 (+6.24%)
This International Pharma Stock Just Hit 5-Year Highs

Teva Pharmaceutical (TEVA) is trading at new 5-year highs. Shares are up more than 40% over the past year. The stock has strong technical momentum, maintaining a 100% “Buy” opinion from Barchart. TEVA...

TEVA : 30.12 (+6.24%)
Is Viatris Stock Outperforming the Dow?

As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

VTRS : 13.51 (+4.24%)
$DOWI : 46,341.51 (+2.49%)
TEVA : 30.12 (+6.24%)
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Enovis (ENOV) and Healthequity (HQY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA – Research Report), Enovis (ENOV – Research Report) and Healthequity (HQY...

ENOV : 22.75 (+4.89%)
HQY : 83.57 (+2.57%)
TEVA : 30.12 (+6.24%)
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

Johnson & Johnson’s JNJ stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since mid-June. It achieved the golden cross in mid-July, after the company announced strong...

JNJ : 244.44 (+0.80%)
KVUE : 17.24 (unch)
TEVA : 30.12 (+6.24%)
AMGN : 351.85 (+0.82%)
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader macroeconomic uncertainties. Here, we discuss...

JNJ : 244.44 (+0.80%)
TEVA : 30.12 (+6.24%)
AMGN : 351.85 (+0.82%)
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

Johnson & Johnson JNJ delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations.Despite the loss of exclusivity (“LOE”) of its multi-billion-dollar product,...

JNJ : 244.44 (+0.80%)
KVUE : 17.24 (unch)
TEVA : 30.12 (+6.24%)
AMGN : 351.85 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets,...

See More

Key Turning Points

3rd Resistance Point 32.04
2nd Resistance Point 31.09
1st Resistance Point 30.61
Last Price 30.12
1st Support Level 29.17
2nd Support Level 28.22
3rd Support Level 27.74

See More

52-Week High 37.35
Last Price 30.12
Fibonacci 61.8% 27.84
Fibonacci 50% 24.91
Fibonacci 38.2% 21.97
52-Week Low 12.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.